Citius Oncology reports positive Phase 1 data for LYMPHIR prior to CAR-T in DLBCL

CITIUS ONCOLOGY, INC.

Overall response rate 86% (57% complete response, 29% partial response) at one month in 14 patients.
One-year progression-free survival 77% (95% CI 43-92%); overall survival 84% (95% CI 49-96%).
LYMPHIR well-tolerated with no dose-limiting toxicities; no Grade ≥3 LYMPHIR-related immune AEs.
Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL); supports larger trial.
Study enrolled high-risk relapsed/refractory DLBCL patients; all proceeded to CAR-T infusion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.